60
Participants
Start Date
November 30, 2008
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
MESENDO
For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
placebo
For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
TCA Cellular Therapy, Covington
Lead Sponsor
TCA Cellular Therapy
INDUSTRY